CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
ALXN1840drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05303324
NCT05303324Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Open-Label, 2-Way Crossover Study to Assess the Single-Dose Pharmacokinetics of ALXN1840 Enteric-Coated Tablets at 2 Dose Strengths in Healthy Adult Subjects

Alexion Pharmaceuticals, Inc.·interventional·Posted Mar 31, 2022·Updated Aug 2, 2023

In Brief

A Phase 1 clinical trial evaluating ALXN1840 for Healthy. Completed, enrolled 48 participants across 1 site.

Detailed Summary

To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMar 31, 2022
Enrollment StartJul 4, 2019
Primary CompletionOct 9, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.3 years ago

Interventions

ALXN1840drug

Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.